When was Ray Therapeutics founded?

Ray Therapeutics was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Ray Therapeutics located?

Ray Therapeutics is headquartered in Berkeley, United States.

Who is the current CEO of Ray Therapeutics?

Paul Bresge of Ray Therapeutics. They have also founded 1 company.

How many employees does Ray Therapeutics have?

As of May 31, 2026, the latest employee count at Ray Therapeutics is 42.

Is Ray Therapeutics a funded company?

Ray Therapeutics is a funded company, having raised a total of $231M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 04, 2022.

When was the latest funding round of Ray Therapeutics?

Ray Therapeutics' latest funding was a $***** Series B round on Apr 21, 2026, with participation from 11 investors.

Where does Ray Therapeutics rank among its competitors?

Ray Therapeutics ranks 19th amongst 111 active competitors, of which 46 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was AAVantgarde Bio, which secured $141M in Nov, 2025.

Who are the top competitors of Ray Therapeutics?

Ray Therapeutics' top competitors include CureVac, Rezolute and EyePoint Pharmaceuticals. Among them, Ray Therapeutics secured the most recent funding round in April, 2026.

Ray Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutics for degenerative retinal diseases. The lead candidate RAY-001 for Retinitis pigmentosa, RAY-002 for geography atrophy, and for other inherited retinal diseases.

Website: raytherapeutics.com
Email ID: *****@raytherapeutics.com

Key Metrics

Founded Year

2021

Location

Berkeley, United States

Stage

Series B

Total Funding

$231M in 6 rounds

Latest Funding Round

Series B, Apr 21, 2026, $*****

Investors

4Bio Capital & 7 more

Ranked

19^th among 111 active competitors

Employee Count

42 as on May 31, 2026

Similar Companies

CureVac & 114 more

View Ray Therapeutics' full profile

Ray Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Ray Therapeutics, Inc. CIN: 862056423 , United States, Active	Dec 31, 2020	-	16 (As on Dec 31, 2024)	-

Ray Therapeutics has raised a total funding of $231M over 6 rounds. Its first funding round was on Jan 04, 2022. Its latest funding round was a Series B round on Apr 21, 2026 for $*****. 11 investors participated in its latest round. Ray Therapeutics has 8 institutional investors.

Here is the list of recent funding rounds of Ray Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 21, 2026	5810459	Series B	6040159	2965421	5641506	9777671
Apr 24, 2025	2576866	Grant (prize money)	9774252	2915798	1871365	CIRM
Nov 13, 2023	3673004	Grant (prize money)	5473069	1815844	2005854	State of California

Access funding benchmarks and valuations. Sign up today!

View details of Ray Therapeutics's funding rounds and investors

The founders of Ray Therapeutics is Paul Bresge. Paul Bresge is the CEO of Ray Therapeutics.

Here are the details of Ray Therapeutics' key team members:

Paul Bresge: Co-Founder & CEO of Ray Therapeutics.
Contact Info: 1 email address

View details of Ray Therapeutics's Founder profiles and Board Members

Ray Therapeutics' employee count trend

Ray Therapeutics has 42 employees as of May 26. Here is Ray Therapeutics's employee count trend over the years:

Employee count trend for Ray Therapeutics

Uncover Ray Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ray Therapeutics include CureVac, Rezolute and EyePoint Pharmaceuticals. Here is the list of Top 10 competitors of Ray Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	CureVac 2000, Tubingen (Germany), Acquired	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	Dievini, Gates Foundation & 16 others	67/100
2nd	Rezolute 2012, Denver (United States), Public	Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI)	-	BVF Partners, Citadel & 8 others	66/100
3rd	EyePoint Pharmaceuticals 1987, Watertown (United States), Public	Developer of small molecule-based therapeutics for treating ophthalmic disorders	-	SWK Holdings, Rosalind Advisors & 3 others	66/100
4th	Kala Pharmaceuticals 2009, Waltham (United States), Public	Developer of ophthalmic treatments based on its mucosal penetrating product platform	$115M	Lux Capital, Third Rock Ventures & 17 others	66/100
5th	Aviceda Therapeutics 2018, Cambridge (United States), Series C	Developer of biotherapeutics for glycol-immune diseases	$255M	Omega Funds, Logos & 10 others	63/100
6th	Epicrispr Bio 2018, San Francisco (United States), Series B	Developer of therapeutics for multiple disease	$68M	Ally Bridge Group, LDV Partners & 1 others	63/100
7th	Molecular Partners 2004, Zurich (Switzerland), Public	Developer of therapeutic solutions for treating multiple diseases	$59.9M	Index Ventures, EW Healthcare Partners & 4 others	63/100
8th	AAVantgarde Bio 2021, Milano (Italy), Series B	Developer of gene therapies using Adeno-Associated Viral vectors	$206M	Atlas Venture, Forbion & 11 others	62/100
9th	Complement Therapeutics 2020, London (United Kingdom), Series A	Developer of gene therapies to treat retinal diseases	$84.8M	Forbion, Gimv & 7 others	59/100
10th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	58/100
19th	Ray Therapeutics 2021, Berkeley (United States), Series B	Developer of therapeutics for degenerative retinal diseases	$231M	Deerfield, CIRM & 6 others	58/100